Xlear
- Business Wire
Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray in Help in Combating SARS-CoV-2
WASHINGTON–(BUSINESS WIRE)–#COVID19–Xlear has filed a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA) seeking approval…
Read More » - Health
New Study Concludes Xlear Kills and/or Deactivates SARS-CoV-2; Efficacy Against New Variants
Using electron microscopy, we have visual evidence showing that xylitol and grapefruit seed extract (GSE) counters the virus. The GSE…
Read More » - United States
Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray to Help in Combating SARS-CoV-2
Washington, United States: Today, Xlear is filing a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration…
Read More » - COVID-19
New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2
Miami, United States: New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective…and replicable…
Read More »